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BACKGROUND: In advanced renal cell carcinoma (RCC), sunitinib and sorafenib tyrosine kinase inhibitors (TKI) are associated
with several clinical side effects, with no definitive established data concerning their clinical impact.
METHODS: From June 2006 to June 2008, main clinical TKI-induced toxicities, including digestive, cardiac, dermatologic and asthenia
were retrospectively collected using the NCI-CTC version 3.0 in patients treated with TKI for an RCC.
RESULTS: The median overall survival was significantly improved in patients with grade 3–4 clinical toxicities (36 vs 12 months,
P¼0.009). In multivariate analysis, the Memorial Sloan-Kettering Cancer Center risk groups (good vs intermediate or poor) and
clinical toxicities (grade 3–4 vs 1–2) were identified as independent prognostic factors of better survival (P¼0.002 and P¼0.02,
respectively). The Charlson comorbidity index score (47 vs o7) was identified as independent predictive factor of severe clinical
TKI-induced toxicities (P¼0.02).
CONCLUSION: In this unselected patients of RCC, clinical TKI-related severe toxicities were more frequent in patients with
comorbidities and were associated with better survival.
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Sunitinib (SU011248) and sorafenib (BAY 43-9006) are two oral
multitargeted tyrosine kinase inhibitors (TKIs) available since late
2006 and early 2007, and both have been subsequently used
as first-line agents in selected patients with advanced renal cell
carcinoma (RCC; Escudier et al, 2007, 2010; Motzer et al, 2007;
Powles et al, 2011). In randomised trials, the more frequent clinical
adverse events reported with sunitinib and sorafenib were,
respectively, fatigue in 51% and 37%, gastrointestinal disorders
including diarrhoea in 53% and 48%, and nausea in 44% and 23%,
hypertension in 24% and 17%, skin toxicities with rash or
desquamation in 19% and 40%, and hand–foot syndrome in
20% and 30% of cases. Some grade 3–4 were also observed with
respectively diarrhoea in 5% and 2%, nausea in approximately 3%,
hypertension in 8% and 4%, rash or desquamation in less than
1%, hand–foot syndrome in 6% and 8%, and fatigue in 7% and 5%
(Escudier et al, 2007; Motzer et al, 2007). Until now, analysis of
TKI-induced toxicities has been mainly descriptive, using a global
evaluation and counting of adverse events occurring in patients
selected for randomised studies. On the basis of this approach, the
impact of TKI related-toxicities on outcome has not yet been
definitively established. Moreover, active monitoring for adverse
reactions, careful management of related toxicities and dose
adaptation during TKI exposure are recommended, but are not yet
modulated according to patient characteristics (Escudier et al,
2010; Schmidinger and Bellmunt, 2010; Bellmunt et al, 2011). We
retrospectively evaluated the predictive factors and the impact on
the outcome of this grade 3–4 clinical TKI toxicities in an
unselected population of patients treated for RCC.
MATERIALS AND METHODS
From June 2006 to June 2008, all consecutive patients with RCC
treated with sunitinib or sorafenib were included and classified
according to the Memorial Sloan-Kettering Cancer Center
(MSKCC) risk score (Motzer et al, 1999). For each patient, we
collected all clinical characteristics, as well as toxicities according
to NCI-CTC version 3. Comorbidities present at TKI initiation
such as hypertension, diabetes, dyslipidemia, renal insufficiency,
alcohol consumption and previous history of cancer were also
analysed, and the Charlson comorbidity index was calculated as
previously described (Charlson et al, 1987). One cycle of sunitinib
consisted of 4 consecutive weeks followed by 2 weeks break (dose
of 50mg per day), whereas one cycle of sorafenib consisted of
4 consecutive weeks without discontinuation (dose of 400mg twice
daily). Patient follow-up was routinely performed at day 1, 14 and
28 of the first treatment cycle, and at least, monthly during
TKI exposure. Predictive factors of the main clinical toxicities
regarding digestive, cardiac, dermatologic and asthenia adverse
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sevents occurring during TKI sequences and prognostic factors of
overall survival (OS) were respectively analysed, using a logistic
regression and a Cox model.
RESULTS
We analysed 53 TKI sequences from 38 patients; 14 received
sunitinib, 9 received sorafenib and 15 received both TKI (Table 1).
The mean time of exposure was 268±298 days, with 313±317
days for sunitinib and 213±271 days for sorafenib (NS). All
toxicities grades were observed in 88.7% of all sequences with
digestive in 73.6%, cardiac in 64.1%, dermatologic in 52.3% and
asthenia in 52.3%. Grade 3–4 toxicities were observed in 51%, and
the most frequent were cardiac in 31.2% and dermatologic in 8.6%.
Grade 3–4 cardiac toxicities were more frequent during sunitinib
sequences (45% vs 12.5%, P¼0.02), whereas grade 3–4 dermato-
logic effects and percentage of dose reduction were more often
observed during sorafenib (33.3% vs 7%, P¼0.03 and 40.6% vs
17.2%, P¼0.02). In the multivariate analysis including gender,
MSKCC risk groups, type of TKI, tumour grade and the Charlson
comorbidity index score (47 vs o7), the comorbidity index score
was identified as an independent predictive factor of TKI-induced
toxicities (P¼0.02, HR: 4.48; IC 95: 1.18–16.9; Table 1).
According to the MSKCC score, the 2-year survival rate was 78%
in patients with low and intermediate vs 36% in poor risk
(P¼0.05). The median OS was 36 months in patients with grade
3–4 clinical toxicities as compared with 12 months in patients
without toxicities (P¼0.009; Figure 1). Moreover, in patients with
an age-adjusted Charlson score 47, the median OS was 12 months
vs 36 months in patients Charlson score o7( P¼0.009). In
patients with WHO performance status at 2, 1 and 0, the median
OS was 6 months vs 9 months vs 39 months, respectively
(P¼0.0005). In the multivariate analysis, the MSKCC risk groups
(good vs intermediate or poor) and severe clinical toxicities (grade
3–4 vs grade 1–2) were identified as independent prognostic
factors of survival (P¼0.002; HR: 0.10; IC 95: 0.02–0.43 and
P¼0.02; HR: 5.55; IC 95: 1.23–24.9, respectively; Table 2).
DISCUSSION
Considering the sample size and the retrospective nature of the
series, our results suggest that grade 3–4 clinical TKI-related
toxicities namely digestive, cardiac, dermatologic and asthenia
were associated with a significant improvement of OS. In a series
of 40 patients with RCC, Rixe et al (2007) have reported that
toxicities limited to grade 3 hypertension was associated with
response and outcome in patients treated with sunitinib. More
recently, Rini et al (2011) reported in a retrospective pooled
analysis from four studies of patients with RCC that sunitinib-
associated hypertension was associated with improved clinical
outcomes. Interestingly, survival rates were close to those observed
in our work with a median OS at 30.9 months in patients who
experienced hypertension vs 7.2 months in patients who did not.
Some similar observations were reported in other malignan-
cies, suggesting a potential prognostic impact of the main target
therapies-related side effects. In advanced intestinal stromal
Table 1 Patients characteristic
Total n¼38
N (%)
Sex
Male 25 (65.8)
Female 13 (34.2)
Age, years (mean, ±s.d.) 62.7±11.5
WHO performance status
0 24 (63.2)
1 11 (28.9)
2 3 (7.9)
Comorbidity 20 (39.5)
Charlson comorbidity score index
a
Non-adjusted (mean, ±s.d.) 7.1±1.2
Ajusted (mean, ±s.d.) 8.8±2.1
Tumour grade
I 2 (5.3)
II 12 (31.6)
III 15 (39.4)
IV 9 (23.7)
Tumour type
Clear cell 32 (86.5)
Other 6 (13.5)
MSKCC risk groups
b
Favourable 9 (23.7)
Intermediate 21 (55.3)
Poor 8 (21.0)
Abbreviation: MSKCC¼Memorial Sloan-Kettering Cancer Center.
aBased on
Charlson et al (1987).
bBased on Motzer et al (1999).
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Figure 1 Overall survival. The median overall survival was 12 months in
patients without grade 3–4 clinical toxicities vs 36 months in patients with
grade 3–4 clinical toxicities (P¼0.009).
Table 2 Multivariate analysis
P-value HR IC 95
Predictive factors of severe clinical TKI toxicities
a
Sex (F vs M) 0.16 0.21 0.03–1.35
Charlson adjusted comorbidity index
b (47 vs o7) 0.02 4.48 1.18–16.9
MSKCC risk groups
c (good vs intermediate or poor) 0.79 1.21 0.28–5.21
Type of TKI (sunitinib vs sorafenib) 0.49 1.51 0.45–5.03
Tumour grade (I–II vs III–IV) 0.85 0.88 0.22–3.46
Prognostic factors of survival
Sex (F vs M) 0.13 2.17 0.78–6.03
Charlson adjusted comorbidity index
b (47 vs o7) 0.30 2.04 0.52–8.0
MSKCC risk groups
c (good vs intermediate or poor) 0.002 0.10 0.02–0.43
Type of TKI (sunitinib vs sorafenib) 0.23 1.83 0.67–5.03
Tumour grade (I–II vs III–IV) 0.97 1.01 0.34–2.98
Clinical toxicities
a (I–II vs III–IV) 0.02 5.55 1.23–24.9
Abbreviations: F¼female; M¼male; MSKCC¼Memorial Sloan-Kettering Cancer
Center; TKI¼tyrosine kinase inhibitors.
aBased on the NCI-CTC version 3.0.
bBased
on Charlson et al (1987).
cBased on Motzer et al (1999).
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sdigestive tumours, George et al (2011) reported that hypertension
level was a predictive factor of response in patients treated with
imatinib. In metastatic colorectal cancer patients treated with
anti-EGFR monoclonal antibodies, it has been reported that skin
rash may be a prognostic factor, and a study is currently ongoing
to evaluate the anti-EGFR dose escalation according to skin
toxicity (Van Cutsem et al, 2009). In contrast to monoclonal
antibodies, TKIs inhibit multiple tyrosine kinase and were, in fact,
associated with several non-VEGF-related biological and clinical
side effects such as those investigated in our study. Although the
exact mechanisms of these non-VEGF-related side effects are
currently undetermined, several factors have been proposed such
as the binding affinities for tyrosine kinase receptors, the cellular
level of these receptors, and also previous treatment and pre-
existing comorbidities (Schmidinger and Bellmunt, 2010). Combi-
nation of these factors could partially explain the different toxicity
between TKI that we observed with more frequent grade 3–4
cardiac toxicities during sunitinib and more dermatological side
effects during sorafenib. We also found that patient comorbidities
may be associated with grade 3–4 clinical TKI-induced toxicities
and was also correlated with OS. In a study on unselected patients
treated with sunitinib, van der Veldt et al (2008) reported that
occurrence of overall grade 3–4 toxicities was significantly
associated with age, body surface and gender, but the Charlson
comorbidity index was not used, and the impact on survival was
also not reported. In contrast, we added the Charlson comorbidity
index to other common baseline parameters and we found that it
was significantly associated with clinical grade 3–4 TKI toxicities.
Until now, the most widely used clinical score is the Charlson
comorbidity index (Charlson et al, 1987). This score was
constructed using a study of 559 patients and its ability to predict
the 1-year mortality was secondary validated on a cohort of women
with breast cancer. The non-adjusted score encompassing
19 medical conditions weighted 1–6, with total scores ranging
from 0 to 37. Age was also identified as a prognostic factor in the
validation set with one point added to the score for each decade
of life over the age of 50 (Charlson et al, 1987). Whatever the
malignancy, randomised trials do not strictly reflect patient
characteristics from cohort routinely treated in cancer units.
Indeed, patients included in these studies often presented a good
general health status, whereas patients with several comorbid
conditions are preferentially referred to other therapeutics. As a
result, in previous randomised trials using sunitinib and sorafenib
in RCC, patients were analysed according to common baseline
characteristics, but the evaluation of comorbid conditions by
specific index, such as Charslon score, and the impact on tolerance
and outcome have not been performed (Escudier et al, 2007;
Motzer et al, 2007). These findings suggested that clinical TKI
related-side effects may be in relation with patient conditions and
may be also a marker of drug efficacy. Therefore, early and
intensive monitoring during treatment exposure remains a
major concern for a careful toxicity management, as well as
dose adaptation. As regards the potential prognostic impact of
TKI-induced side effects, evaluation of specific supportive
measures, particularly in patients with high risk of toxicities,
may be of interest, to ensure an optimal drug exposure in the field
of sequential use of biological agents in RCC.
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